|Bid||170.01 x 900|
|Ask||176.76 x 800|
|Day's Range||172.81 - 177.58|
|52 Week Range||119.29 - 184.83|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.78|
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 21, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open.
A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?